RxDoctor Payments Data

Robert Baker

Psychiatric/Mental Health · Los Angeles, CANPI 1689225427

Payments from drug & device makers

$6,836in general payments, 2019–2025

Across 128 payments — averaging $53.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Neurocrine Biosciences, Inc.$2K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Otsuka America Pharmaceutical, Inc.$621
  • Alpha Cognition USA, Inc.$528
  • E.r. Squibb & Sons, L.L.C.$347
  • plus $716 from 9 others

What the payments were for

  • Food & beverage$6,830100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,836 in reported general payments places this provider in the 90th percentile of 2,433 psychiatric/mental health providers in California.

See all psychiatric/mental health providers in California

Medicare billing

Part B allowed, 2024
$668,525
Medicare patients
1,379
Services billed
10,512

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate183$1,318,298
RexultiBrexpiprazole213$176,459
Ziprasidone Mesylate14$2,861
Buspirone Hcl141$2,824
Olanzapine34$1,773
Temazepam52$1,002
Lorazepam120$936
Escitalopram Oxalate79$931
Risperidone62$774
Bupropion Hcl19$664
Quetiapine Fumarate27$645
Clonazepam34$436
Aripiprazole16$364
Sertraline Hcl34$344
Fluoxetine Hcl27$286

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$1,562$1,318,298183 claims
Otsuka America Pharmaceutical, Inc.Rexulti$621$176,459213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,433 psychiatric/mental health providers in California.

Other psychiatric/mental health in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →